NASDAQ$THRD
Third Harmonic Bio Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Announced third quarter 2024 financial results.
Third Harmonic Bio reported a net loss of $13.8 million for the third quarter of 2024, with cash and cash equivalents totaling $296.1 million as of September 30, 2024.
- THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25.
- Cash and cash equivalents totaled $296.1 million as of September 30, 2024.
- R&D expenses increased to $11.3 million for the three months ended September 30, 2024, from $6.0 million for the same period in 2023.
- Net loss for the three months ended September 30, 2024, increased to $13.8 million from a net loss of $7.3 million for the same period in 2023.
Headline financials
Revenue & EPS history
Third Harmonic · Revenue · Quarterly
$0
Forward guidance
Third Harmonic Bio believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through at least 2026.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports · overlaid with Q3 2024
+1.0%
Avg return
Earnings day
+14.2%
Avg return
5 days after
+13.0%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+13.0%
Q3 2024
Best reaction
-11.1%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +0.6% | -0.2% | +5.8% | |
| Q4 2024 | -1.1% | +42.1% | +41.9% | |
| Q3 2024 | +13.0% | +13.0% | -11.2% | |
| Q2 2024 | +10.6% | +11.5% | +9.2% | |
| Q1 2024 | +10.2% | +11.8% | +3.3% | |
| Q4 2023 | +8.0% | +7.1% | +29.2% | |
| Q3 2023 | +0.8% | — | — | |
| Q2 2023 | -6.4% | — | — | |
| Q1 2023 | -11.1% | — | — | |
| Q4 2022 | -3.5% | — | — | |
| Q3 2021 | -1.2% | — | — | |
| Q4 2021 | -1.2% | — | — | |
| Q3 2022 | -1.2% | — | — | |
| Q1 2022 | -1.2% | — | — | |
| Q2 2022 | -1.2% | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro